MindBio Therapeutics Explores Dual Listing Amid Successful Clinical Trials

MindBio Therapeutics Corp. announced its intent for a potential dual listing on senior exchanges in the United States or Australia, amidst ongoing and successful clinical trials. The biopharma company, listed on the Canadian Securities Exchange and Frankfurt, has completed positive Phase 1 and 2a trials, including a Phase 2a for its drug MB22001, which showed significant reduction in depressive symptoms among patients with Major Depressive Disorder.

The company is now undertaking two significant Phase 2B trials with MB22001, a proprietary form of LSD intended for microdosing. These trials, including a world-first take-home use approval, focus on various mental health issues. MindBio plans to commence Phase 3 trials in 2025, becoming one of the few public companies to reach this advanced stage in psychedelic medicine.